NEW YORK--(BUSINESS WIRE)--Feb. 17, 2006--ZIOPHARM Oncology, Inc. (OTC BB: ZIOP) presented preclinical data today at the 2006 Bone Marrow Transplant Meetings in Honolulu demonstrating that ZIO-201, the Company’s proprietary alkylating agent, may have a role in conditioning for bone marrow transplants. The data was presented by Lee Roy Morgan M.D., Ph.D., Robert Peter Gale, M.D., Ph.D., and colleagues.
